Life Insurance with Type 2 Diabetes: Qualifying for Standard Rates

Well-controlled Type 2 diabetics regularly qualify for standard-rate life insurance in 2026. A1C is the single most important underwriting input, with readings below 7.0 opening the door to standard or better rates at multiple carriers. Other factors that affect the rating include medications, complications, age at diagnosis, trend over time, and unrelated cardiovascular risk factors. Matching the applicant's specific profile to a carrier whose guidelines favor that profile is the work that produces standard rates where another broker might produce a Table 4.

Why A1C Is the Primary Input

A1C measures average blood glucose over the preceding three months by testing the percentage of hemoglobin that has glycated (bonded with glucose). The American Diabetes Association establishes the clinical targets: below 5.7 percent is nondiabetic, 5.7 to 6.4 indicates prediabetes, 6.5 or above establishes a diabetes diagnosis.

For underwriting purposes, carriers use A1C as the single most reliable signal of diabetic control. Unlike fasting glucose, A1C cannot be manipulated by temporary behavior changes before a blood draw. It reflects sustained management over the preceding three months, which is what underwriters need to assess mortality risk accurately.

A carrier's underwriting guidelines typically include A1C bands, each corresponding to a rate class or range. The bands vary between carriers, and guidelines shift quarter to quarter based on each company's claims experience and actuarial updates.

A1C Thresholds by Rate Class (2026 General Ranges)

The following reflect general market norms in early 2026 across the major life insurance carriers. Individual carriers deviate in both directions, and all rate classes assume clean supporting factors (no significant complications, controlled blood pressure and cholesterol, stable weight).

• Below 7.0: Best chance at standard or standard plus rates. A small number of carriers will consider preferred classes for applicants diagnosed after age 40 with consistent sub-7.0 readings over multiple years, no complications, and no concurrent cardiovascular conditions. Preferred classes remain uncommon for Type 2 diabetics even under these conditions.
• 7.0 to 7.5: Standard rates achievable at select carriers. Some carriers rate Table 2 (roughly 50 percent premium loading). Match matters: Lincoln Financial, Pacific Life, and John Hancock have historically been more accommodating in this band than Prudential or Mutual of Omaha.
• 7.5 to 8.0: Typically Table 2 to Table 4 at most carriers. A few will still issue standard depending on the broader picture (clean complications, recent improvement trend, active management with GLP-1 agents).
• 8.0 to 8.5: Table 4 to Table 6 at most carriers. Standard is rare but occasionally available with a strong supporting case.
• Above 8.5: Ratings get heavier. Some carriers decline. Others issue at Table 8 or higher. Graded-benefit final expense policies become a more relevant option at the upper end.

These are working thresholds. A particular carrier's guidelines in any given quarter may differ meaningfully.

What Else Moves the Rating

A1C does not determine the rate class alone. Underwriters evaluate the full clinical picture.

Age at Diagnosis

Diagnosis at 28 with an A1C of 7.0 reads differently to an underwriter than diagnosis at 58 with the same A1C. Later diagnosis with good control is viewed more favorably because the disease progression risk profile differs. Applicants diagnosed after age 50 with consistent A1C under 7.0 regularly qualify for standard rates.

Medication Regimen

Medications signal disease stage to underwriters. The general hierarchy:

• Metformin alone: Earlier-stage or well-managed disease. Favorable for underwriting.
• Metformin plus one other oral agent (DPP-4 inhibitor, SGLT2 inhibitor): Still generally favorable if A1C is well-controlled.
• GLP-1 agonist (Ozempic, Wegovy, Mounjaro, Trulicity): Increasingly viewed as a positive signal in 2026 because GLP-1s are associated with active weight management and cardiovascular benefit. Carriers adapted their guidelines in 2024-2025 to reflect this.
• Insulin, particularly in combination with oral medications: Signals more advanced disease. Pushes ratings toward Table 2 to Table 4 at most carriers even with well-controlled A1C.

Complications

The presence or absence of diabetic complications carries significant weight:

• Retinopathy: Any grade pushes ratings up. Proliferative retinopathy is often a decline trigger.
• Neuropathy: Mild peripheral neuropathy may be absorbed into Table 2. More severe cases push higher.
• Nephropathy (kidney involvement): Elevated creatinine or microalbuminuria push ratings significantly. Stage 3 chronic kidney disease or worse often triggers decline.
• Cardiovascular disease: Any established coronary disease or prior event pushes ratings well above the base diabetes rating.

A clean complications picture is load-bearing for standard-rate placement. A Type 2 diabetic with A1C 7.2 and no complications is a very different case from one with A1C 7.2, microalbuminuria, and mild retinopathy.

Trend Over Time

A single favorable reading matters less than a documented trend. An applicant with three consecutive A1C readings moving from 8.2 to 7.4 to 6.9 over 18 months is a much stronger case than one with a single 6.9 reading and unknown history. Underwriters interpret the trend as active management.

Conversely, readings that have deteriorated over time (6.8 to 7.4 to 8.1) raise questions about disease progression and are viewed skeptically even if the most recent reading is favorable.

Other Cardiovascular Risk Factors

Blood pressure, cholesterol, BMI, and smoking stack with diabetes in the underwriter's risk calculation. Well-controlled Type 2 diabetes with clean blood pressure (under 135/85), favorable lipids (LDL under 130, HDL over 40), BMI under 30, and nonsmoker status often qualifies for standard. The same diabetic profile with hypertension, elevated LDL, BMI 35, and recent smoking history faces Table 4 or worse.

Why the Right Carrier Match Matters

Two carriers with similar market reputations can reach very different underwriting decisions on the same Type 2 diabetic. Company A might rate every Type 2 diabetic at A1C 7.2 as Table 2 as a matter of table-based guideline. Company B might issue standard at 7.2 with clean supporting factors. The difference is not arbitrary: it reflects each carrier's actuarial approach and recent claims experience.

An independent broker who works across carriers tracks these variances in real time. When a diabetic applicant comes in, the first step is not a formal application. It is an informal underwriting inquiry to two to four carriers whose guidelines are likely to favor the specific profile. Each carrier returns a tentative rate class. The applicant proceeds formally only with the carrier offering the best match, and the unsuccessful inquiries leave no trace.

This process regularly produces placements at standard rates for applicants who were told by another broker to expect Table 2 or Table 4. The case did not change. The carrier did.

Information to Gather Before Inquiring

A productive informal inquiry requires specific documentation:

• Most recent A1C reading with date
• A1C readings from the prior 2 to 3 years if available from the primary care physician
• Current medication list with dosages and prescribing physician
• Date of initial diabetes diagnosis
• Most recent fasting lipid panel
• Blood pressure readings from the preceding 6 months
• Any complications documented in the medical record (retinopathy, neuropathy, nephropathy, cardiovascular)
• Height and current weight
• Smoking status and history if applicable

With this information, the broker can assemble a case summary that directly addresses the questions underwriters will ask. A thin submission ("I'm diabetic, what can I get?") produces thin answers. A complete submission with lab trends and clean complications produces meaningful tentative offers.

Frequently Asked Questions

Can a Type 2 Diabetic Qualify for Preferred Rates?

Rarely. A small number of carriers consider preferred classes for applicants diagnosed after age 40, with consistent sub-7.0 A1C readings over multiple years, no complications, no concurrent cardiovascular conditions, and clean supporting factors. Most carriers exclude diabetics from preferred classes entirely. Standard is the realistic ceiling for most well-controlled Type 2 diabetics.

Does Using a GLP-1 Agent Help or Hurt Underwriting?

In 2026, most carriers view GLP-1 agents (Ozempic, Wegovy, Mounjaro, Trulicity) as positive signals because they are associated with active weight management, A1C reduction, and cardiovascular benefit. This represents a shift from 2022-2023, when some carriers treated any new medication as a recent-instability flag. Guidelines have adapted as the clinical evidence for GLP-1 benefit has strengthened.

What Happens if A1C Has Improved Significantly Before Applying?

An improvement trend supports the underwriting case. A carrier will want to see documented A1C readings over time, not just the most recent value. Applicants who have reduced A1C from 8.5 to 6.9 over 12 to 18 months of active management (diet, exercise, medication adjustment) should wait until the trend is documented before applying. The rate class at 6.9 with a documented improvement trend is often better than the rate class at 6.9 with unknown history.

Are There Carriers That Specialize in Diabetic Life Insurance?

No carrier specializes exclusively in diabetic applicants, but several have guidelines that are more accommodating than the market average for well-controlled Type 2 cases. Lincoln Financial, John Hancock, Pacific Life, and Prudential have each had favorable stretches in recent years. Current standings shift quarter to quarter and are best assessed at the time of inquiry.

How Does Type 1 Diabetes Differ From Type 2 for Underwriting?

Type 1 diabetes generally results in more conservative underwriting because the disease requires lifelong insulin therapy, carries higher complication risk over a lifetime, and typically begins at earlier ages. Standard rates are achievable for Type 1 diabetics with excellent control and no complications, but the rating threshold is tighter than for Type 2. Type 1 applicants benefit particularly from an informal inquiry approach.

What if the A1C Is Above 9.0?

Traditional fully-underwritten life insurance becomes difficult above A1C 9.0. Options at that level typically include simplified-issue no-medical-exam policies with higher premiums and lower coverage limits, or graded-benefit final expense policies with reduced payouts in the early years. For applicants actively working to improve control, a better strategy is often waiting 9 to 12 months to re-inquire with documented improvement.

Does Blood Pressure Medication Hurt the Case?

Not necessarily. Blood pressure medication demonstrates active management of a controlled condition, which underwriters generally view positively. The concern is uncontrolled hypertension, not treated hypertension. An applicant on two or three antihypertensives with well-controlled readings (under 135/85 consistently) is viewed more favorably than an applicant on no medication with readings at 145/95.

The Practical Path Forward

Type 2 diabetics who want to understand what life insurance is actually available to them should work with an independent broker who will conduct an informal inquiry across appropriate carriers before any formal application. The inquiry costs nothing, creates no record, and surfaces the realistic rate class range from multiple carriers.

Pacific Direct Insurance works with diabetic applicants regularly. Interested applicants can request a quote or call (714) 941-0234. Related reading includes the full guide to life insurance with diabetes, how the informal inquiry process works, and what to do after a life insurance decline.